Bharat Biotech

Bharat Biotech’s Intranasal COVID-19 vaccine gets CDSCO approval

iNCOVACC is the world’s first Intranasal vaccine for COVID to receive approval for the primary 2-dose schedule, and heterologous booster dose

Nearly 50 million doses of Covaxin expected to expire in early 2023 due to low product demand

Bharat Biotech has more than 200 million doses of Covaxin in bulk form and approximately 50 million doses in vials ready to use. Due to lack of product demand, production stoppage of Covaxin was initiated several months ago, earlier this year, say sources

Bharat Biotech gets nod for India's first nasal COVID vaccine: Why this is a potential game-changer

Bharat Biotech says the vaccine is easy to administer as it is non-invasive and does not require trained healthcare workers. It also eliminates needle-associated risks such as injuries and infections and is scalable when it comes to manufacturing

COVID-19: India's first nasal vaccine by Bharat Biotech gets drug panel's nod for 'restricted use'

The Central Drugs Standard Control Organisation has approved the vaccine for primary immunisation against COVID-19 in the above 18 age group for 'restricted use in an emergency situation'

Bharat Biotech's Rotavac introduced in Nigeria to immunise children from diarrhoea

Nigeria currently accounts for 14 per cent of all childhood rotavirus deaths globally, making it the country with the second-highest number of rotavirus deaths in the world

Nasal vaccine: A futuristic intervention in immunisation drive

Nasal vaccines are easier to administer, especially it would be a great relief for people who are afraid of needles and for children and the elderly population as it is non-invasive

Bharat Biotech completes clinical development for phase III trials, booster doses for BBV154 intranasal COVID vaccine

BBV154 has the double benefit of enabling faster development of variant-specific vaccines and easy nasal delivery that helps mass immunisation protect from emerging concern variants

200 crore vaccinations: How India under Narendra Modi scripted Covid success story

The country crossed a record 200 crore Covid-19 vaccinations on 17 July 2022 within barely 18 months of launching this exercise on 16 January last year

Covaxin safe, well-tolerated in 2-18 years age-group, announces Bharat Biotech

The clinical trial conducted in the paediatric population between June 2021 to September 2021 has shown safety, less reactogenic, and robust immunogenicity

Germany to recognise Bharat Biotech's COVID-19 vaccine Covaxin for travel from 1 June

In November last year, the World Health Organisation recommended Emergency Use Listing (EUL) status for Covaxin